Novocure Reports Data from the P-III (METIS) Study of Stereotactic Radiosurgery in NSCLC Patients
Shots:
- The P-III (METIS) study assesses stereotactic radiosurgery with/without TTFields therapy vs SoC in patients (n=298) with 1-10 brain metastases from NSCLC
- The study met the 1EP demonstrating a median time to intracranial progression of 21.9mos. vs 11.3mos. and median TTFields therapy treatment duration of 16wks. with a median usage of 67%. The tolerability of TTFields was consistent with the prior evaluations showing sustained quality of life & neurocognitive function
- The preliminary analysis of 2EPs incl. time to neurocognitive failure, OS & radiological response rate was not significant while time to distant progression & quality of life were in favor of TTFields therapy. Further evaluation is underway
Ref: Novocure | Image: Novocure
Related News:- Zai Lab and Novocure Report P-III Trial (LUNAR) Results of Tumor Treating Fields Therapy for Metastatic Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
